<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Access to Pharmaceuticals</title>
	<atom:link href="http://www.accesstopharmaceuticals.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.accesstopharmaceuticals.org</link>
	<description>Latest News and Views from the Access to Pharmaceuticals Consortium</description>
	<lastBuildDate>Mon, 23 Apr 2012 17:13:11 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>New publication from the ATP consortium</title>
		<link>http://www.accesstopharmaceuticals.org/2012/04/23/new-publication-from-the-atp-consortium/</link>
		<comments>http://www.accesstopharmaceuticals.org/2012/04/23/new-publication-from-the-atp-consortium/#comments</comments>
		<pubDate>Mon, 23 Apr 2012 17:11:23 +0000</pubDate>
		<dc:creator>harry</dc:creator>
				<category><![CDATA[Publications]]></category>
		<category><![CDATA[Case studies]]></category>
		<category><![CDATA[IVI]]></category>
		<category><![CDATA[PDP]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=602</guid>
		<description><![CDATA[A paper arising from the ATP project that reviews case studies relating to product development and delivery by selected product development partnerships (PDP) is available as an open access publication:
Title: Product Development Partnerships: Case studies of a new mechanism for health technology innovation.
Journal: Health Research Policy and Systems 2011, 9:33
Author: Richard Mahoney. International Vaccine Institute [...]]]></description>
			<content:encoded><![CDATA[<p>A paper arising from the ATP project that reviews case studies relating to product development and delivery by selected product development partnerships (PDP) is available as an open access publication:</p>
<p>Title: Product Development Partnerships: Case studies of a new mechanism for health technology innovation.</p>
<p>Journal: Health Research Policy and Systems 2011, 9:33</p>
<p>Author: Richard Mahoney. International Vaccine Institute (IVI)</p>
<p>There is a continuing need for new health technologies to address the disease burdens of developing countries. In the last decade Product Development Partnerships (PDP) have emerged that are making important contributions to the development of these technologies. PDPs are a form of public private partnerships that focus on health technology development. PDPs reflect the current phase in the history of health technology development: the Era of Partnerships, in which the public and private sectors have found productive ways to collaborate. Successful innovation depends on addressing six determinants of innovation. We examine four case studies of PDPs and show how they have addressed the six determinants to achieve success.</p>
<p>Download the paper <a href="http://www.accesstopharmaceuticals.org/wp-content/uploads/2012/04/Mahoney-HARPS-ATP-1478-4505-9-33.pdf">here</a> &#8230;.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2012/04/23/new-publication-from-the-atp-consortium/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Publication on Socially Responsible Licensing Initiatives in South Africa</title>
		<link>http://www.accesstopharmaceuticals.org/2011/07/29/new-publication-on-socially-responsible-licensing-initiatives-in-south-africa/</link>
		<comments>http://www.accesstopharmaceuticals.org/2011/07/29/new-publication-on-socially-responsible-licensing-initiatives-in-south-africa/#comments</comments>
		<pubDate>Fri, 29 Jul 2011 11:09:08 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Publications]]></category>
		<category><![CDATA[Socially Responsible Licencing]]></category>
		<category><![CDATA[South Africa]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=596</guid>
		<description><![CDATA[The objectives of Socially Responsible Licensing (SRL) are mainly to ensure that licensing of intellectual assets is negotiated and transacted in a manner conducive to providing access to essential medicines and other life enhancing innovations. The goals of SRL are to make available to society globally, but in particular to developing countries, such technologies at [...]]]></description>
			<content:encoded><![CDATA[<p>The objectives of Socially Responsible Licensing (SRL) are mainly to ensure that licensing of intellectual assets is negotiated and transacted in a manner conducive to providing access to essential medicines and other life enhancing innovations. The goals of SRL are to make available to society globally, but in particular to developing countries, such technologies at affordable prices and to make proprietary research tools widely available for the advancement of knowledge. This can be achieved by adopting licensing practices which add a dimension of social responsibility to the pursuit of economic objectives, without necessarily compromising the latter. This approach does not affect business transactions in developed countries where significant profits can still be achieved but ensures access for the least developed countries, which are often disregarded in commercialization strategies due to perceived low profitability. This paper addresses recent developments in South Africa, specifically the newly enacted legislation on IP emanating from publicly funded research, and some practical examples of how SRL strategies can be implemented.</p>
<p><a href="http://www.accesstopharmaceuticals.org/wp-content/uploads/2010/02/Socially_Responsible_Licensing_Of_Health_Technologies_Policy_And_Practice_In_South_Africa.pdf">Socially Responsible Licensing Of Health Technologies- Policy And Practice In South Africa</a></p>
<p>Rabogajane Busang, Karine Boisjoly-Letourneau, Bernard Fourie, Michelle Mulder and Harry Thangaraj</p>
<p>Journal of the Licensing Executives Society International (<em>les Nouvelles</em>).  June, 2011 &#8211; Volume XLVI No. 2</p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2011/07/29/new-publication-on-socially-responsible-licensing-initiatives-in-south-africa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New publication on R&amp;D for Neglected Diseases from the University of Neuchâtel</title>
		<link>http://www.accesstopharmaceuticals.org/2010/11/02/publicationneuchatel/</link>
		<comments>http://www.accesstopharmaceuticals.org/2010/11/02/publicationneuchatel/#comments</comments>
		<pubDate>Tue, 02 Nov 2010 15:59:24 +0000</pubDate>
		<dc:creator>Sandy</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[neglected diseases]]></category>
		<category><![CDATA[Neuchâtel]]></category>
		<category><![CDATA[UNINE]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=576</guid>
		<description><![CDATA[Neuchâtel, 18 October 2010. How can biomedical and pharmaceutical research and development be stimulated in Switzerland in order to fight neglected diseases (Chagas, Dengue fever or river blindness)? A researcher of the Institute of Health  Law at the University  of Neuchâtel sheds light on this question in a book that has just been [...]]]></description>
			<content:encoded><![CDATA[<p><strong>Neuchâtel, 18 October 2010. </strong>How can biomedical and pharmaceutical research and development be stimulated in Switzerland in order to fight neglected diseases (Chagas, Dengue fever or river blindness)? A researcher of the Institute of Health  Law at the University  of Neuchâtel sheds light on this question in a book that has just been released. <a href="http://www.accesstopharmaceuticals.org/about/institutions-unine/" target="_blank">Read more on the UNINE page&#8230;</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2010/11/02/publicationneuchatel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Compulsory licensing of an antiretroviral in Brazil</title>
		<link>http://www.accesstopharmaceuticals.org/2010/06/02/compulsory-licensing-of-an-antiretroviral-in-brazil/</link>
		<comments>http://www.accesstopharmaceuticals.org/2010/06/02/compulsory-licensing-of-an-antiretroviral-in-brazil/#comments</comments>
		<pubDate>Wed, 02 Jun 2010 13:44:40 +0000</pubDate>
		<dc:creator>harry</dc:creator>
				<category><![CDATA[Case studies]]></category>
		<category><![CDATA[brazil]]></category>
		<category><![CDATA[compulsory]]></category>
		<category><![CDATA[efavirenz]]></category>
		<category><![CDATA[fiocruz]]></category>
		<category><![CDATA[merck]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=469</guid>
		<description><![CDATA[As part of our research on compulsory licensing we have now added a case study on efavirenz &#8211; the antiretroviral that Brazil needed for its public funded HIV treatment program. Brazil was forced to do so because of failure of negotiation for a voluntary license by the patent holder, Merck. This case is the first [...]]]></description>
			<content:encoded><![CDATA[<p>As part of our research on compulsory licensing we have now added a case study on efavirenz &#8211; the antiretroviral that Brazil needed for its public funded HIV treatment program. Brazil was forced to do so because of failure of negotiation for a voluntary license by the patent holder, Merck. This case is the first addition to a new section entitled: <a href="http://www.accesstopharmaceuticals.org/case-studies-in-global-health">Case Studies in Global Health</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2010/06/02/compulsory-licensing-of-an-antiretroviral-in-brazil/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>St. George’s Global Health Forum, and local UAEM Chapter</title>
		<link>http://www.accesstopharmaceuticals.org/2010/05/17/st-george%e2%80%99s-global-health-forum-and-local-uaem-chapter/</link>
		<comments>http://www.accesstopharmaceuticals.org/2010/05/17/st-george%e2%80%99s-global-health-forum-and-local-uaem-chapter/#comments</comments>
		<pubDate>Mon, 17 May 2010 12:34:11 +0000</pubDate>
		<dc:creator>Sandy</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[GHF]]></category>
		<category><![CDATA[St George's]]></category>
		<category><![CDATA[UAEM]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=441</guid>
		<description><![CDATA[Global Health Forum (GHF) was set up by graduate students on the MBBS 4 course in 2007. On coming to St Georges these students felt there could be more opportunities to learn about global health issues, and share news and ideas within the medical school. Through sending monthly emails about various Global health events in [...]]]></description>
			<content:encoded><![CDATA[<p>Global Health Forum (GHF) was set up by graduate students on the MBBS 4 course in 2007. On coming to St Georges these students felt there could be more opportunities to learn about global health issues, and share news and ideas within the medical school. Through sending monthly emails about various Global health events in London and getting speakers in to St Georges twice termly GHF aims to be a platform from which these ideas can be discussed and spread. <a href="http://www.accesstopharmaceuticals.org/about/institutions-sgul/nciih/">Read more about our activities and creation of a local UAEM (universities allied for essential medicines) chapter at St George&#8217;s&#8230; </a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2010/05/17/st-george%e2%80%99s-global-health-forum-and-local-uaem-chapter/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Welcome to the ATP blog</title>
		<link>http://www.accesstopharmaceuticals.org/2009/10/07/welcome-to-the-atp-blog/</link>
		<comments>http://www.accesstopharmaceuticals.org/2009/10/07/welcome-to-the-atp-blog/#comments</comments>
		<pubDate>Wed, 07 Oct 2009 11:03:38 +0000</pubDate>
		<dc:creator>harry</dc:creator>
				<category><![CDATA[Announcements]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=119</guid>
		<description><![CDATA[This is our space for news, opinion and announcements
]]></description>
			<content:encoded><![CDATA[<p>This is our space for news, opinion and announcements</p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2009/10/07/welcome-to-the-atp-blog/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PDP 2009 Workshop</title>
		<link>http://www.accesstopharmaceuticals.org/2009/02/08/pdp200/</link>
		<comments>http://www.accesstopharmaceuticals.org/2009/02/08/pdp200/#comments</comments>
		<pubDate>Sun, 08 Feb 2009 12:06:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Meeting report]]></category>
		<category><![CDATA[IVI]]></category>
		<category><![CDATA[PDP workshop]]></category>

		<guid isPermaLink="false">http://www.accesstopharmaceuticals.org/?p=123</guid>
		<description><![CDATA[Rich Mahoney from the IVI has kindly made available the presentations and meetings from the 2009 PDP workshop in New York in the staff pages.
]]></description>
			<content:encoded><![CDATA[<p>Rich Mahoney from the IVI has kindly made available the presentations and meetings from the 2009 PDP workshop in New York in the<a href="http://www.accessmed.org/consortium-staff-pages/"> staff pages</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.accesstopharmaceuticals.org/2009/02/08/pdp200/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

